- en: <!--yml
  id: totrans-split-0
  prefs: []
  type: TYPE_NORMAL
  zh: <!--yml
- en: 'category: 未分类'
  id: totrans-split-1
  prefs: []
  type: TYPE_NORMAL
  zh: 'category: 未分类'
- en: 'date: 2024-05-27 13:33:20'
  id: totrans-split-2
  prefs: []
  type: TYPE_NORMAL
  zh: 'date: 2024-05-27 13:33:20'
- en: -->
  id: totrans-split-3
  prefs: []
  type: TYPE_NORMAL
  zh: -->
- en: Cost of developing new drugs may be far lower than industry claims, trial reveals
    | Global development | The Guardian
  id: totrans-split-4
  prefs:
  - PREF_H1
  type: TYPE_NORMAL
  zh: 药物开发成本可能远低于行业声称的试验揭示 | 全球发展 | 卫报
- en: 来源：[https://www.theguardian.com/global-development/2024/apr/25/cost-of-developing-new-drugs-may-be-far-lower-than-industry-claims-trial-reveals](https://www.theguardian.com/global-development/2024/apr/25/cost-of-developing-new-drugs-may-be-far-lower-than-industry-claims-trial-reveals)
  id: totrans-split-5
  prefs:
  - PREF_BQ
  type: TYPE_NORMAL
  zh: 来源：[《卫报》全球发展专栏](https://www.theguardian.com/global-development/2024/apr/25/cost-of-developing-new-drugs-may-be-far-lower-than-industry-claims-trial-reveals)
- en: Doctors have for the first time released details of their spending on a major
    clinical trial, demonstrating that the true cost of developing a medicine may
    be far less than the billions of dollars claimed by the pharmaceutical industry.
  id: totrans-split-6
  prefs: []
  type: TYPE_NORMAL
  zh: 医生们首次公布了一项重大临床试验的支出细节，显示出开发药物的真实成本可能远低于制药行业声称的数十亿美元。
- en: Médecins Sans Frontières (MSF) is challenging drug companies to be transparent
    about the cost of trials, which has always been shrouded in secrecy. Its own bill
    for landmark trials of a four-drug combination treatment for drug-resistant tuberculosis
    came to €34m (£29m).
  id: totrans-split-7
  prefs: []
  type: TYPE_NORMAL
  zh: 医生无国界组织（MSF）正在挑战药企对试验成本保持透明，试验成本向来被笼罩在神秘之中。对于治疗耐药结核病的四种药物联合疗法的重要试验，其账单总计为€34m（£29m）。
- en: '<gu-island name="SignInGateSelector" '
  id: totrans-split-8
  prefs: []
  type: TYPE_NORMAL
  zh: '<gu-island name="SignInGateSelector" '
- en: 'priority="feature" '
  id: totrans-split-9
  prefs: []
  type: TYPE_NORMAL
  zh: 'priority="feature" '
- en: 'deferuntil="visible" '
  id: totrans-split-10
  prefs: []
  type: TYPE_NORMAL
  zh: 'deferuntil="visible" '
- en: 'props="{&quot;contentType&quot;:&quot;Article&quot;,&quot;sectionId&quot;:&quot;global-development&quot;,&quot;tags&quot;:[{&quot;id&quot;:&quot;global-development/series/fair-access&quot;,&quot;type&quot;:&quot;Series&quot;,&quot;title&quot;:&quot;Fair
    Access&quot;},{&quot;id&quot;:&quot;global-development/global-development&quot;,&quot;type&quot;:&quot;Keyword&quot;,&quot;title&quot;:&quot;Global
    development&quot;},{&quot;id&quot;:&quot;global-development/global-health&quot;,&quot;type&quot;:&quot;Keyword&quot;,&quot;title&quot;:&quot;Global
    health&quot;},{&quot;id&quot;:&quot;society/health&quot;,&quot;type&quot;:&quot;Keyword&quot;,&quot;title&quot;:&quot;Health&quot;},{&quot;id&quot;:&quot;business/pharmaceuticals-industry&quot;,&quot;type&quot;:&quot;Keyword&quot;,&quot;title&quot;:&quot;Pharmaceuticals
    industry&quot;},{&quot;id&quot;:&quot;society/society&quot;,&quot;type&quot;:&quot;Keyword&quot;,&quot;title&quot;:&quot;Society&quot;},{&quot;id&quot;:&quot;business/business&quot;,&quot;type&quot;:&quot;Keyword&quot;,&quot;title&quot;:&quot;Business&quot;},{&quot;id&quot;:&quot;society/tuberculosis&quot;,&quot;type&quot;:&quot;Keyword&quot;,&quot;title&quot;:&quot;Tuberculosis&quot;},{&quot;id&quot;:&quot;type/article&quot;,&quot;type&quot;:&quot;Type&quot;,&quot;title&quot;:&quot;Article&quot;},{&quot;id&quot;:&quot;tone/news&quot;,&quot;type&quot;:&quot;Tone&quot;,&quot;title&quot;:&quot;News&quot;},{&quot;id&quot;:&quot;profile/sarahboseley&quot;,&quot;type&quot;:&quot;Contributor&quot;,&quot;title&quot;:&quot;Sarah
    Boseley&quot;,&quot;bylineImageUrl&quot;:&quot;https://i.guim.co.uk/img/uploads/2017/12/27/Sarah-Boseley.jpg?width=300&amp;quality=85&amp;auto=format&amp;fit=max&amp;s=f9e63028641ded092dfa778117da5717&quot;,&quot;bylineLargeImageUrl&quot;:&quot;https://i.guim.co.uk/img/uploads/2017/12/27/Sarah_Boseley,_R.png?width=300&amp;quality=85&amp;auto=format&amp;fit=max&amp;s=6420ea135e3ed73c4f59e4f9c408401f&quot;},{&quot;id&quot;:&quot;tracking/commissioningdesk/global-development&quot;,&quot;type&quot;:&quot;Tracking&quot;,&quot;title&quot;:&quot;UK
    Global Development&quot;}],&quot;isPaidContent&quot;:false,&quot;isPreview&quot;:false,&quot;host&quot;:&quot;https://www.theguardian.com&quot;,&quot;pageId&quot;:&quot;global-development/2024/apr/25/cost-of-developing-new-drugs-may-be-far-lower-than-industry-claims-trial-reveals&quot;,&quot;idUrl&quot;:&quot;https://profile.theguardian.com&quot;,&quot;switches&quot;:{&quot;lightbox&quot;:true,&quot;prebidAppnexusUkRow&quot;:true,&quot;mastheadWithHighlights&quot;:false,&quot;abSignInGateMainVariant&quot;:true,&quot;commercialMetrics&quot;:true,&quot;prebidTrustx&quot;:true,&quot;scAdFreeBanner&quot;:false,&quot;adaptiveSite&quot;:true,&quot;prebidPermutiveAudience&quot;:true,&quot;compareVariantDecision&quot;:false,&quot;enableSentryReporting&quot;:true,&quot;lazyLoadContainers&quot;:true,&quot;ampArticleSwitch&quot;:true,&quot;remarketing&quot;:true,&quot;articleEndSlot&quot;:true,&quot;keyEventsCarousel&quot;:true,&quot;updateLogoAdPartner&quot;:true,&quot;registerWithPhone&quot;:false,&quot;darkModeWeb&quot;:true,&quot;targeting&quot;:true,&quot;remoteHeader&quot;:true,&quot;slotBodyEnd&quot;:true,&quot;prebidImproveDigitalSkins&quot;:true,&quot;ampPrebidOzone&quot;:true,&quot;extendedMostPopularFronts&quot;:true,&quot;emailInlineInFooter&quot;:true,&quot;showNewPrivacyWordingOnEmailSignupEmbeds&quot;:true,&quot;abDeeplyReadRightColumn&quot;:true,&quot;prebidAnalytics&quot;:true,&quot;extendedMostPopular&quot;:true,&quot;ampContentAbTesting&quot;:false,&quot;prebidCriteo&quot;:true,&quot;okta&quot;:true,&quot;imrWorldwide&quot;:true,&quot;acast&quot;:true,&quot;automaticFilters&quot;:true,&quot;twitterUwt&quot;:true,&quot;updatedHeaderDesign&quot;:true,&quot;prebidAppnexusInvcode&quot;:true,&quot;ampPrebidPubmatic&quot;:true,&quot;a9HeaderBidding&quot;:true,&quot;prebidAppnexus&quot;:true,&quot;enableDiscussionSwitch&quot;:true,&quot;prebidXaxis&quot;:true,&quot;stickyVideos&quot;:true,&quot;interactiveFullHeaderSwitch&quot;:true,&quot;discussionAllPageSize&quot;:true,&quot;prebidUserSync&quot;:true,&quot;audioOnwardJourneySwitch&quot;:true,&quot;brazeTaylorReport&quot;:false,&quot;externalVideoEmbeds&quot;:true,&quot;abSignInGateAlternativeWording&quot;:false,&quot;callouts&quot;:true,&quot;sentinelLogger&quot;:true,&quot;geoMostPopular&quot;:true,&quot;weAreHiring&quot;:false,&quot;relatedContent&quot;:true,&quot;thirdPartyEmbedTracking&quot;:true,&quot;prebidOzone&quot;:true,&quot;ampLiveblogSwitch&quot;:true,&quot;ampAmazon&quot;:true,&quot;prebidAdYouLike&quot;:true,&quot;mostViewedFronts&quot;:true,&quot;discussionInApps&quot;:false,&quot;optOutAdvertising&quot;:true,&quot;abSignInGateMainControl&quot;:true,&quot;googleSearch&quot;:true,&quot;brazeSwitch&quot;:true,&quot;darkModeInApps&quot;:true,&quot;prebidKargo&quot;:true,&quot;consentManagement&quot;:true,&quot;personaliseSignInGateAfterCheckout&quot;:true,&quot;redplanetForAus&quot;:true,&quot;prebidSonobi&quot;:true,&quot;idProfileNavigation&quot;:true,&quot;confiantAdVerification&quot;:true,&quot;discussionAllowAnonymousRecommendsSwitch&quot;:false,&quot;dcrTagPages&quot;:true,&quot;absoluteServerTimes&quot;:false,&quot;permutive&quot;:true,&quot;comscore&quot;:true,&quot;ampPrebidCriteo&quot;:true,&quot;tagLinkDesign&quot;:false,&quot;abMpuWhenNoEpic&quot;:false,&quot;newsletterOnwards&quot;:false,&quot;youtubeIma&quot;:true,&quot;webFonts&quot;:true,&quot;prebidImproveDigital&quot;:true,&quot;abAdBlockAsk&quot;:false,&quot;ophan&quot;:true,&quot;crosswordSvgThumbnails&quot;:true,&quot;prebidTriplelift&quot;:true,&quot;weather&quot;:true,&quot;prebidPubmatic&quot;:true,&quot;serverShareCounts&quot;:false,&quot;autoRefresh&quot;:true,&quot;enhanceTweets&quot;:true,&quot;prebidIndexExchange&quot;:true,&quot;prebidOpenx&quot;:true,&quot;prebidHeaderBidding&quot;:true,&quot;idCookieRefresh&quot;:true,&quot;discussionPageSize&quot;:true,&quot;smartAppBanner&quot;:false,&quot;boostGaUserTimingFidelity&quot;:false,&quot;historyTags&quot;:true,&quot;brazeContentCards&quot;:true,&quot;surveys&quot;:true,&quot;remoteBanner&quot;:true,&quot;emailSignupRecaptcha&quot;:true,&quot;prebidSmart&quot;:true,&quot;shouldLoadGoogletag&quot;:true,&quot;inizio&quot;:true}}" '
  id: totrans-split-11
  prefs: []
  type: TYPE_NORMAL
  zh: props="{&quot;contentType&quot;:&quot;Article&quot;,&quot;sectionId&quot;:&quot;global-development&quot;,&quot;tags&quot;:[{&quot;id&quot;:&quot;global-development/series/fair-access&quot;,&quot;type&quot;:&quot;Series&quot;,&quot;title&quot;:&quot;公平获取&quot;},{&quot;id&quot;:&quot;global-development/global-development&quot;,&quot;type&quot;:&quot;Keyword&quot;,&quot;title&quot;:&quot;全球发展&quot;},{&quot;id&quot;:&quot;global-development/global-health&quot;,&quot;type&quot;:&quot;Keyword&quot;,&quot;title&quot;:&quot;全球健康&quot;},{&quot;id&quot;:&quot;society/health&quot;,&quot;type&quot;:&quot;Keyword&quot;,&quot;title&quot;:&quot;健康&quot;},{&quot;id&quot;:&quot;business/pharmaceuticals-industry&quot;,&quot;type&quot;:&quot;Keyword&quot;,&quot;title&quot;:&quot;制药行业&quot;},{&quot;id&quot;:&quot;society/society&quot;,&quot;type&quot;:&quot;Keyword&quot;,&quot;title&quot;:&quot;社会&quot;},{&quot;id&quot;:&quot;business/business&quot;,&quot;type&quot;:&quot;Keyword&quot;,&quot;title&quot;:&quot;商业&quot;},{&quot;id&quot;:&quot;society/tuberculosis&quot;,&quot;type&quot;:&quot;Keyword&quot;,&quot;title&quot;:&quot;结核病&quot;},{&quot;id&quot;:&quot;type/article&quot;,&quot;type&quot;:&quot;Type&quot;,&quot;title&quot;:&quot;文章&quot;},{&quot;id&quot;:&quot;tone/news&quot;,&quot;type&quot;:&quot;Tone&quot;,&quot;title&quot;:&quot;新闻&quot;},{&quot;id&quot;:&quot;profile/sarahboseley&quot;,&quot;type&quot;:&quot;Contributor&quot;,&quot;title&quot;:&quot;萨拉·博斯利&quot;,&quot;bylineImageUrl&quot;:&quot;https://i.guim.co.uk/img/uploads/2017/12/27/Sarah-Boseley.jpg?width=300&amp;quality=85&amp;auto=format&amp;fit=max&amp;s=f9e63028641ded092dfa778117da5717&quot;,&quot;bylineLargeImageUrl&quot;:&quot;https://i.guim.co.uk/img/uploads/2017/12/27/Sarah_Boseley,_R.png?width=300&amp;quality=85&amp;auto=format&amp;fit=max&amp;s=6420ea135e3ed73c4f59e4f9c408401f&quot;},{&quot;id&quot;:&quot;tracking/commissioningdesk/global-development&quot;,&quot;type&quot;:&quot;Tracking&quot;,&quot;title&quot;:&quot;英国全球发展&quot;}],&quot;isPaidContent&quot;:false,&quot;isPreview&quot;:false,&quot;host&quot;:&quot;https://www.theguardian.com&quot;,&quot;pageId&quot;:&quot;global-development/2024/apr/25/cost-of-developing-new-drugs-may-be-far-lower-than-industry-claims-trial-reveals&quot;,&quot;idUrl&quot;:&quot;https://profile.theguardian.com&quot;,&quot;switches&quot;:{&quot;lightbox&quot;:true,&quot;prebidAppnexusUkRow&quot;:true,&quot;mastheadWithHighlights&quot;:false,&quot;abSignInGateMainVariant&quot;:true,&quot;commercialMetrics&quot;:true,&quot;prebidTrustx&quot;:true,&quot;scAdFreeBanner&quot;:false,&quot;adaptiveSite&quot;:true,&quot;prebidPermutiveAudience&quot;:true,&quot;compareVariantDecision&quot;:false,&quot;enableSentryReporting&quot;:true,&quot;lazyLoadContainers&quot;:true,&quot;ampArticleSwitch&quot;:true,&quot;remarketing&quot;:true,&quot;articleEndSlot&quot;:true,&quot;keyEventsCarousel&quot;:true,&quot;updateLogoAdPartner&quot;:true,&quot;registerWithPhone&quot;:false,&quot;darkModeWeb&quot;:true,&quot;targeting&quot;:true,&quot;remoteHeader&quot;:true,&quot;slotBodyEnd&quot;:true,&quot;prebidImproveDigitalSkins&quot;:true,&quot;ampPrebidOzone&quot;:true,&quot;extendedMostPopularFronts&quot;:true,&quot;emailInlineInFooter&quot;:true,&quot;showNewPrivacyWordingOnEmailSignupEmbeds&quot;:true,&quot;abDeeplyReadRightColumn&quot;:true,&quot;prebidAnalytics&quot;:true,&quot;extendedMostPopular&quot;:true,&quot;ampContentAbTesting&quot;:false,&quot;prebidCriteo&quot;:true,&quot;okta&quot;:true,&quot;imrWorldwide&quot;:true,&quot;acast&quot;:true,&quot;automaticFilters&quot;:true,&quot;twitterUwt&quot;:true,&quot;updatedHeaderDesign&quot;:true,&quot;prebidAppnexusInvcode&quot;:true,&quot;ampPrebidPubmatic&quot;:true,&quot;a9HeaderBidding&quot;:true,&quot;prebidAppnexus&quot;:true,&quot;enableDiscussionSwitch&quot;:true,&quot;prebidXaxis&quot;:true,&quot;stickyVideos&quot;:true,&quot;interactiveFullHeaderSwitch&quot;:true,&quot;discussionAllPageSize&quot;:true,&quot;prebidUserSync&quot;:true,&quot;audioOnwardJourneySwitch&quot;:true,&quot;brazeTaylorReport&quot;:false,&quot;externalVideoEmbeds&quot;:true,&quot;abSignInGateAlternativeWording&quot;:false,&quot;callouts&quot;:true,&quot;sentinelLogger&quot;:true,&quot;geoMostPopular&quot;:true,&quot;weAreHiring&quot;:false,&quot;relatedContent&quot;:true,&quot;thirdPartyEmbedTracking&quot;:true,&quot;prebidOzone&quot;:true,&quot;ampLiveblogSwitch&quot;:true,&quot;ampAmazon&quot;:true,&quot;prebidAdYouLike&quot;:true,&quot;mostViewedFronts&quot;:true,&quot;discussionInApps&quot;:false,&quot;optOutAdvertising&quot;:true,&quot;abSignInGateMainControl&quot;:true,&quot;googleSearch&quot;:true,&quot;brazeSwitch&quot;:true,&quot;darkModeInApps&quot;:true,&quot;prebidKargo&quot;:true,&quot;consentManagement&quot;:true,&quot;personaliseSignInGateAfterCheckout&quot;:true,&quot;redplanetForAus&quot;:true,&quot;prebidSonobi&quot;:true,&quot;idProfileNavigation&quot;:true,&quot;confiantAdVerification&quot;:true,&quot;discussionAllowAnonymousRecommendsSwitch&quot;:false,&quot;dcrTagPages&quot;:true,&quot;absoluteServerTimes&quot;:false,&quot;permutive&quot;:true,&quot;comscore&quot;:true,&quot;ampPrebidCriteo&quot;:true,&quot;tagLinkDesign&quot;:false,&quot;abMpuWhenNoEpic&quot;:false,&quot;newsletterOnwards&quot;:false,&quot;youtubeIma&quot;:true,&quot;webFonts&quot;:true,&quot;prebidImproveDigital&quot;:true,&quot;abAdBlockAsk&quot;:false,&quot;ophan&quot;:true,&quot;crosswordSvgThumbnails&quot;:true,&quot;prebidTriplelift&quot;:true,&quot;weather&quot;:true,&quot;prebidPubmatic&quot;:true,&quot;serverShareCounts&quot;:false,&quot;autoRefresh&quot;:true,&quot;enhanceTweets&quot;:true,&quot;prebidIndexExchange&quot;:true,&quot;prebidOpenx&quot;:true,&quot;prebidHeaderBidding&quot;:true,&quot;idCookieRefresh&quot;:true,&quot;discussionPageSize&quot;:true,&quot;smartAppBanner&quot;:false,&quot;boostGaUserTimingFidelity&quot;:false,&quot;historyTags&quot;:true,&quot;brazeContentCards&quot;:true,&quot;surveys&quot;:true,&quot;remoteBanner&quot;:true,&quot;emailSignupRecaptcha&quot;:true,&quot;prebidSmart&quot;:true,&quot;shouldLoadGoogletag&quot;:true,&quot;inizio&quot;:true}}"
- en: config="{&quot;renderingTarget&quot;:&quot;Web&quot;,&quot;darkModeAvailable&quot;:false,&quot;inAdvertisingPartnerABTest&quot;:false,&quot;assetOrigin&quot;:&quot;https://assets.guim.co.uk/&quot;}"></gu-island>
  id: totrans-split-12
  prefs: []
  type: TYPE_NORMAL
  zh: config="{&quot;renderingTarget&quot;:&quot;Web&quot;,&quot;darkModeAvailable&quot;:false,&quot;inAdvertisingPartnerABTest&quot;:false,&quot;assetOrigin&quot;:&quot;https://assets.guim.co.uk/&quot;}"></gu-island>
- en: Current estimates for research and development of new medicines range from €40m
    to €3.9bn. The extortionate cost of trials is used to justify high prices of new
    medicines, but companies do not publish either the topline or a breakdown of their
    spending. MSF says this opacity should end. It has produced a toolkit for drug
    trialists, which categorises each item of expenditure and allows the costs to
    be collated throughout the process, which can last for years.
  id: totrans-split-13
  prefs: []
  type: TYPE_NORMAL
  zh: 目前估计新药研发的研究和开发费用范围从4千万欧元到39亿欧元不等。试验的高昂成本被用来为新药的高价辩护，但公司既不公布总支出也不公布支出的细分。MSF表示，这种不透明性应该结束。它已经为药物试验人员制定了一个工具包，将每一项支出分类，并允许在持续数年的过程中汇总成本。
- en: MSF’s trial, called TB Practecal, has transformed prospects for people with
    drug-resistant forms of TB, which have high mortality rates and in some countries
    have been untreatable because of the high price of the few drugs that still work.
  id: totrans-split-14
  prefs: []
  type: TYPE_NORMAL
  zh: MSF的TB Practecal试验已经改变了患有抗药性结核病形式的人的前景，这些形式具有高死亡率，并且在一些国家由于仍有效的少数药物的高价而无法治疗。
- en: 'Dr Bern-Thomas Nyang’wa, MSF’s medical director and the chief investigator
    of the trial, said: “We hope that our disclosure of clinical trial costs for identifying
    an improved regimen for drug-resistant tuberculosis will serve as a clarion call
    for other public and nonprofit actors to join us and publicly share their clinical
    trial costs to ensure broader transparency in medical R&D costs.”'
  id: totrans-split-15
  prefs: []
  type: TYPE_NORMAL
  zh: 梅卫尔斯无国界医生（MSF）的医学主任及试验的首席调查员Bern-Thomas Nyang’wa博士表示：“我们希望，我们公开抗药性结核病临床试验成本的举措，能够唤起其他公共和非营利性机构的共鸣，公开分享他们的临床试验成本，以确保医学研发成本更广泛的透明度。”
- en: 'He added: “We encourage clinical trial sponsors and implementors to try our
    Transparency Core toolkit, and to build on it as a guide to facilitate the publication
    of cost data. While transparency in R&D expenditure remains largely elusive, transparency
    in clinical trial costs is a transformative step towards exposing what medical
    innovation actually costs and building a future where access to medicines and
    medical tools is not hindered by high prices.”'
  id: totrans-split-16
  prefs: []
  type: TYPE_NORMAL
  zh: 他补充道：“我们鼓励临床试验的赞助者和实施者尝试我们的透明核心工具包，并以此作为指南，促进成本数据的发布。虽然研发支出的透明度仍然很难实现，但临床试验成本的透明度是向揭示医学创新实际成本和构建未来，使药物和医疗工具获得不受高价格阻碍的未来的重要一步。”
- en: 'The MSF says it hopes its disclosure will act as a ‘clarion call’ for the industry.
    Photograph: Alexandra Sadokova/MSF'
  id: totrans-split-17
  prefs: []
  type: TYPE_NORMAL
  zh: MSF表示，希望其披露将作为该行业的“呼吁”。图片来源：亚历山德拉·萨多科娃/MSF
- en: The two antimicrobial drugs that have been the staple treatment for TB for decades,
    isoniazid and rifampicin, no longer work as well as they did. The outlook for
    patients with drug-resistant TB has been bleak in middle and low-income countries.
    Even if alternative drugs were available, they had to be taken regularly for an
    entire year.
  id: totrans-split-18
  prefs: []
  type: TYPE_NORMAL
  zh: 多年来作为结核病的主要治疗药物的两种抗菌药物异烟肼和利福平的效果已不如从前。在中低收入国家，对于抗药性结核病患者的前景一直很黯淡。即使有替代药物可用，患者仍需每天定期服用一整年。
- en: Bedaquiline, a new drug with a different mechanism against drug-resistant TB,
    was developed by Johnson & Johnson and, in 2012, became the first TB drug to be
    approved by the Food and Drug Administration in the US in 40 years. But the cost
    was [prohibitive for many of the worst-affected countries](https://www.theguardian.com/global-development/2023/mar/29/victory-over-big-pharma-opens-door-to-cheaper-tuberculosis-drugs-india).
    It took a long battle by campaigners to [get the price reduced](https://www.theguardian.com/global-development/2023/jul/18/cheaper-tb-drugs-for-millions-after-global-deal-on-patent-rights-agreed).
    The cost of R&D was a key factor. Eventually, it was revealed by academics that
    the drug was developed thanks to public funding, which was [five times more](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0239118)
    than private investment.
  id: totrans-split-19
  prefs: []
  type: TYPE_NORMAL
  zh: 贝达喹林是一种针对耐药结核病的新药，由强生公司开发，并在2012年成为美国食品药品监督管理局40年来首个批准的结核病药物。但对许多受影响最严重的国家来说，费用是[难以承受的](https://www.theguardian.com/global-development/2023/mar/29/victory-over-big-pharma-opens-door-to-cheaper-tuberculosis-drugs-india)。倡导者经过长时间的斗争才成功地[降低了价格](https://www.theguardian.com/global-development/2023/jul/18/cheaper-tb-drugs-for-millions-after-global-deal-on-patent-rights-agreed)。研发成本是一个关键因素。最终，学术界揭示了该药物是依靠公共资金开发的，比私人投资[多五倍](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0239118)。
- en: MSF trialled the use of a combination of four oral drugs, including bedaquiline,
    against drug-resistant TB. Its success led to the World [Health](https://www.theguardian.com/society/health)
    Organization (WHO) recommending six months’ treatment with the combination for
    rifampicin-resistant TB. It is now in use in 40 countries.
  id: totrans-split-20
  prefs: []
  type: TYPE_NORMAL
  zh: MSF试验了包括贝达喹林在内的四种口服药物联合治疗耐药结核病。其成功促使世界[卫生组织（WHO）](https://www.theguardian.com/society/health)推荐联合使用这六个月的治疗方案来治疗利福平耐药结核病。目前已在40个国家使用。
- en: 'Roz Scourse, a policy adviser with MSF’s Access Campaign, said: “The global
    movement that pushed for a significant price reduction of the lifesaving TB drug
    bedaquiline demonstrated that transparency of R&D costs can lead to increased
    access to medical tools and help save more lives.'
  id: totrans-split-21
  prefs: []
  type: TYPE_NORMAL
  zh: MSF访问运动的政策顾问Roz Scourse表示：“推动显著降低救命抗结核药物贝达喹林价格的全球运动表明，透明的研发成本可以增加医疗工具的使用，并帮助挽救更多生命。”
- en: '<gu-island name="RichLinkComponent" priority="feature" deferuntil="idle" props="{&quot;richLinkIndex&quot;:11,&quot;element&quot;:{&quot;_type&quot;:&quot;model.dotcomrendering.pageElements.RichLinkBlockElement&quot;,&quot;prefix&quot;:&quot;Related:
    &quot;,&quot;text&quot;:&quot;South Africans take on big pharma for access to
    ‘miracle’ cystic fibrosis drug&quot;,&quot;elementId&quot;:&quot;aeac439f-a2fb-4920-8db0-4617ba025e3d&quot;,&quot;role&quot;:&quot;richLink&quot;,&quot;url&quot;:&quot;https://www.theguardian.com/global-development/2024/mar/18/cystic-fibrosis-patient-south-africa-cheri-nel-lawsuit-big-pharma-generic-drugs-trikafta-access-vertex&quot;},&quot;ajaxUrl&quot;:&quot;https://api.nextgen.guardianapps.co.uk&quot;,&quot;format&quot;:{&quot;display&quot;:0,&quot;theme&quot;:0,&quot;design&quot;:0}}"
    config="{&quot;renderingTarget&quot;:&quot;Web&quot;,&quot;darkModeAvailable&quot;:false,&quot;inAdvertisingPartnerABTest&quot;:false,&quot;assetOrigin&quot;:&quot;https://assets.guim.co.uk/&quot;}"></gu-island>'
  id: totrans-split-22
  prefs: []
  type: TYPE_NORMAL
  zh: '[相关：南非人因获得对‘奇迹’囊性纤维化药物的访问而对大型制药公司提起诉讼](https://www.theguardian.com/global-development/2024/mar/18/cystic-fibrosis-patient-south-africa-cheri-nel-lawsuit-big-pharma-generic-drugs-trikafta-access-vertex)'
- en: “The unsubstantiated yet dominant narrative that high prices are needed to recoup
    high R&D costs can no longer remain an evidence-free zone – this information is
    a critical piece of the policy puzzle that can inform the price of medical products,
    and who gets access.”
  id: totrans-split-23
  prefs: []
  type: TYPE_NORMAL
  zh: “高价用于收回高研发成本”的未经证实但占主导地位的说法，不再可以是没有证据的区域了——这些信息是可以指导医疗产品定价，并影响谁能够获得使用的政策难题的关键部分。
- en: MSF’s paper, presented Thursday at a WHO conference on medicines pricing, showed
    it was possible to collect good data on spending in trials, Scourse said. She
    urged public disclosure, so that governments and communities can have the evidence
    they need to discuss pricing and work towards access for all those who need the
    medicines.
  id: totrans-split-24
  prefs: []
  type: TYPE_NORMAL
  zh: MSF在世界卫生组织关于药品定价的会议上递交的文件显示，可以收集到有关临床试验支出的良好数据，Scourse表示。她呼吁公开披露，以便政府和社区获得他们需要讨论定价并为所有需要药物的人提供访问的证据。
- en: Although MSF’s trials took place in middle-income countries, the costs were
    not low, said Scourse, because they had to invest substantial sums to upgrade
    infrastructure – such as TB clinics – to be able to conduct high-quality research.
  id: totrans-split-25
  prefs: []
  type: TYPE_NORMAL
  zh: 尽管MSF的试验是在中等收入国家进行的，但Scourse说，成本并不低，因为他们不得不投入大量资金来升级基础设施，例如结核病诊所，以便进行高质量的研究。
- en: 'Staff at a clinic in Uzbekistan where the MSF’s TB Pracetcal treatment was
    trialled. Photograph: Alpamis Babaniyazov/MSF'
  id: totrans-split-26
  prefs: []
  type: TYPE_NORMAL
  zh: 在进行了MSF TB实用治疗试验的乌兹别克斯坦的一家诊所的工作人员。照片：Alpamis Babaniyazov/MSF
- en: The pharmaceutical industry trade body, the International Federation of Pharmaceutical
    Manufacturers and Traders (IFPMA), said most estimates for the cost of an approved
    drug ranged from $2.2bn-$3.2bn (£1.7bn-£2.5bn), and pointed to a Deloitte analysis
    from 2022 which put the [average at $2.3bn](https://www2.deloitte.com/ch/en/pages/press-releases/articles/deloitte-pharma-study-drop-off-in-returns-on-r-and-d-investments-sharp-decline-in-peak-sales-per-asset.html).
  id: totrans-split-27
  prefs: []
  type: TYPE_NORMAL
  zh: 国际制药及生物技术协会（IFPMA）表示，大多数批准药物的成本估计为22亿至32亿美元（17亿至25亿英镑），并指出2022年德勤的分析显示[平均为23亿美元](https://www2.deloitte.com/ch/en/pages/press-releases/articles/deloitte-pharma-study-drop-off-in-returns-on-r-and-d-investments-sharp-decline-in-peak-sales-per-asset.html)。
- en: “The pharmaceutical industry invests around $200bn every year on research and
    development,” said James Anderson, IFPMA’s executive director of global health.
    “Over the last 10 years alone, companies have developed over 470 medicines to
    treat diseases such as cancer, cardiovascular diseases and diabetes, as well as
    vaccines to protect against significant infections from malaria, RSV and Covid-19,
    among others.
  id: totrans-split-28
  prefs: []
  type: TYPE_NORMAL
  zh: “每年，制药行业在研究和开发上投资约2000亿美元，” 国际制药及生物技术协会（IFPMA）全球卫生执行董事詹姆斯·安德森说道。“仅过去10年，企业已开发出超过470种药物，用于治疗癌症、心血管疾病、糖尿病以及预防疟疾、RSV和Covid-19等重大感染病的疫苗。
- en: “Medicines should be affordable to healthcare systems, available to patients
    everywhere, and prices must reflect the value that a medicine delivers to societies
    in different countries. This can only be achieved by recognising the value of
    medicines, while engaging in dialogue on how to make innovations more affordable
    and accessible to all.”
  id: totrans-split-29
  prefs: []
  type: TYPE_NORMAL
  zh: “药物应对医疗系统具有经济承受能力，对所有患者都应该是可获得的，药品价格必须反映出其对不同国家社会价值的贡献。这只能通过承认药物的价值，并在如何使创新更加经济实惠和对所有人更加可及方面进行对话来实现。”
